MedTrace Logo

Amr Maneuver for Prevention of Postpartum Hemorrhage

NCT04401839 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2021-02-08

No results posted yet for this study

Summary

The patients were divided randomly in to 2 GROUPS:

* control group: 153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
* study group:156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.

Conditions

  • Post Partum Hemorrhage

Interventions

DRUG

Oxytocin IV shot

Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby

DRUG

Oxytocin IV drip

administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation

PROCEDURE

Amr maneuver

sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-08-31
Completion
2021-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04401839 on ClinicalTrials.gov